Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.
复制标题
效应γδ T 细胞和肿瘤细胞作为多发性骨髓瘤中唑来膦酸的免疫靶标。
作者:
S. Mariani;M. Muraro;F. Pantaleoni;F. Fiore;B. Nuschak;S. Peola;M. Foglietta;A. Palumbo;M. Coscia;B. Castella;B. Bruno;R. Bertieri;L. Boano;M. Boccadoro;M. Massaia
The aim of this study was to investigate the in vitro immunomodulatory effects of zoledronic acid (Zol) on peripheral blood Vgamma9/Vdelta2 (gammadelta) T cells of normal donors and multiple myeloma (MM) patients. gammadelta T cells were stimulated with Zol and low doses of interleukin-2 (IL-2), and then analyzed for proliferation, cytokine production, and generation of effector activity against myeloma cell lines and primary myeloma cells. Proliferation of gammadelta T cells was observed in 100% of normal donors and 50% of MM patients. gammadelta T cells produced IFN-gamma, surface mobilized the CD107a and CD107b antigens, and exerted direct cell-to-cell antimyeloma activity irrespective of the ability to proliferate to Zol and IL-2. The memory phenotype was predominant in the MM gammadelta T cells that proliferated in response to Zol (responders), whereas effector cells were predominant in those that did not (nonresponders). Zol induced antimyeloma activity through the monocyte-dependent activation of gammadelta T cells and by enhancing the immunosensitivity of myeloma cells to gammadelta T cells. Mevastatin, a specific inhibitor of hydroxy-methylglutaryl-CoA reductase, completely abrogated this antimyeloma activity.